Edition:
United Kingdom

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

66.59USD
21 Sep 2018
Change (% chg)

$-1.69 (-2.48%)
Prev Close
$68.28
Open
$68.37
Day's High
$68.64
Day's Low
$66.42
Volume
1,053,071
Avg. Vol
577,206
52-wk High
$118.32
52-wk Low
$60.22

Chart for

About

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI... (more)

Overall

Beta: 0.81
Market Cap(Mil.): $24,161.52
Shares Outstanding(Mil.): 210.65
Dividend: --
Yield (%): --

Financials

  INCY.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.78 -- --
ROI: -11.99 1.78 14.61
ROE: -23.24 3.27 16.33

FDA approves lower dose of Lilly-Incyte arthritis drug

The U.S. Food and Drug Administration on Friday approved the lower dose of a rheumatoid arthritis drug developed by Eli Lilly and Incyte Corp, but declined to approve its higher and more lucrative dose.

01 Jun 2018

FDA approves lower dose of Lilly-Incyte arthritis drug

June 1 The U.S. Food and Drug Administration on Friday approved the lower dose of a rheumatoid arthritis drug developed by Eli Lilly and Incyte Corp, but declined to approve its higher and more lucrative dose.

01 Jun 2018

BRIEF-Incyte Reports Q1 Loss Of $0.19 Per Share

* INCYTE REPORTS 2018 FIRST-QUARTER FINANCIAL RESULTS AND UPDATES ON KEY CLINICAL PROGRAMS

01 May 2018

FDA panel against higher dose of Lilly-Incyte arthritis drug

An arthritis drug developed by Eli Lilly & Co and Incyte Corp should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted on Monday, in a setback to the drugmakers that were counting on the treatment as a future blockbuster.

24 Apr 2018

BRIEF-Immunovaccine And Incyte Expand Clinical Collaboration

* IMMUNOVACCINE AND INCYTE EXPAND CLINICAL COLLABORATION EVALUATING COMBINATION IMMUNOTHERAPIES IN ADVANCED RECURRENT OVARIAN CANCER

24 Apr 2018

UPDATE 2-FDA panel against higher dose of Lilly-Incyte arthritis drug

* Approval in only 2 mg dose limits commercial potential- analysts

23 Apr 2018

FDA panel votes against approving higher dose of Lilly-Incyte arthritis drug

April 23 A U.S. FDA advisory committee voted 10-to-5 on Monday against approving a higher dose of a rheumatoid arthritis drug developed by Eli Lilly & Co and Incyte Corp, but recommended that it be approved in a lower dose.

23 Apr 2018

FDA staff raises safety concerns over Lilly/Incyte arthritis drug

An experimental rheumatoid arthritis drug developed by Eli Lilly and Co and Incyte Corp poses serious risks of deadly blood clots at higher doses, U.S. Food and Drug Administration staff said on Thursday, the latest setback to a treatment regulators declined to approve last year.

19 Apr 2018

UPDATE 2-Incyte tumbles after combo therapy with Merck fails study

April 6 Incyte Corp's shares sank more than 20 percent on Friday after its experimental cancer drug failed to bolster the effectiveness of Merck & Co's blockbuster Keytruda to treat skin cancer patients.

06 Apr 2018

Incyte, Merck melanoma combo therapy fails study, shares slide

Incyte Corp said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with Merck & Co's Keytruda failed to meet the main goal in a late-stage study.

06 Apr 2018

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $44.06 +0.31
Abbott Laboratories (ABT.N) $69.05 +0.26
Amgen, Inc. (AMGN.OQ) $205.10 0.00
Biogen Inc (BIIB.OQ) $345.41 +4.17
Roche Holding Ltd. (ROG.S) CHF235.15 +0.10
Roche Holding Ltd. (RO.S) CHF235.40 -1.20
Sanofi SA (SASY.PA) €74.50 -0.17

Earnings vs. Estimates